


BEST AVAILABLE COPY



Express Mail Label No.: EV 669115565 US
Date of Deposit: August , 2005

Attorney Docket No. 350957-0012 RHI-010US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: CLOUATRE, Dallas
TITLE: (-)-HYDROXYCITRIC ACID FOR CONTROLLING
INFLAMMATION
SERIAL NUMBER 10/612,648
FILING DATE July 2, 2003
GROUP ART UNIT 1614

Boston, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER

Dear Sir:

The Petitioner, Glykon Technologies Group, LLC, having its principal place of business at 4560 South Decatur Blvd., Suite 202, Las Vegas, Nevada 89103, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application Serial No. 10/612,648, filed July 2, 2003, by virtue of an Assignment filed and recorded on January 29, 2004, on Reel/Frame 015981/0218, in the United States Patent and Trademark Office. Further, the Petitioner represents that it is the owner of U.S. Patent No. 6,482,858, which issued on U.S. Patent Application No. 09/886,582, filed June 20, 2001, by virtue of an Assignment filed and recorded on June 1, 2005, on Reel/Frame 016323/0717, in the United States Patent and Trademark Office.

The Petitioner hereby disclaims the terminal part of the term of any patent granted on the above identified patent application which would extend beyond the full statutory term, as shortened by any terminal disclaimer, of U.S. Patent 6,482,858, and hereby agrees that any patent so granted on the above identified patent application shall be enforceable only for and during such period that the legal title to U.S. Patent 6,482,858 shall be the same as the legal title to any patent granted on the above identified patent application, this agreement to run with any patent granted on the above identified patent application and to be binding upon the grantee, its successors or assigns.

08/24/2005 BABRAHA1 00000056 503431 10612648

01 FC:2814 65.00 DA

BEST AVAILABLE COPY

FIRST-NAMED INVENTOR: Clouatre
Terminal Disclaimer filed August , 2005

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above identified patent application, prior to the full statutory term of U.S.

Patent 6,482,858 as defined in 35 U.S.C. §§154-156 and 173, in the event that U.S. Patent 6,482,858 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid in a final judgment by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 USC §154, prior to the full statutory term of U.S. Patent 6,482,858 as defined in 35 USC §§154-156 and 173, except for the separation of legal title stated above. Further, Petitioner does not disclaim any terminal part of a patent granted on the above identified patent application that would extend beyond the present termination of U.S. Patent 6,482,858, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§155, 155A or 156, and without waiving Petitioner's right to extend the term of a patent granted on the above identified patent application to the extent provided by law.

The undersigned is duly authorized to act on behalf of Petitioner and certifies to the best of his knowledge and belief, legal title to the above identified patent application and U.S. Patent 6,482,858 rests with Petitioner. The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing therefrom.

Respectfully submitted,

Dated: August 18, 2005


Dallas Clouatre
Glykon Technologies Group, LLC